Expanding Global Public Health Access Through Varicella Vaccine Technology Transfer
Achieved 'A' ESG Ratings: Three Consecutive Years from MSCI, Four Consecutive Years from KCGS

On June 29, SK bioscience announced the publication of its "2026 ESG Report," which details its sustainable growth strategy and performance in environmental, social, and governance (ESG) management. This year’s report discloses key ESG activities and achievements, such as climate change response, public health promotion, and responsible management, in line with the global trend toward reinforced ESG disclosure standards.


SK Bioscience headquarters building. SK Bioscience

SK Bioscience headquarters building. SK Bioscience

View original image

In the environmental sector, the company broadened the scope of its greenhouse gas management. SK bioscience refined its calculation standards and completed third-party verification not only for direct emissions (Scope 1 and 2) from business sites, but also for indirect emissions (Scope 3) across the entire supply chain, including raw material procurement, logistics, and distribution.


Additionally, by utilizing the Taskforce on Nature-related Financial Disclosures (TNFD) framework, the company assessed the impact of its business activities on the natural environment and biodiversity, and disclosed its corresponding response strategies.


In the social sector, the report highlights SK bioscience’s contributions to global public health as a vaccine specialist. The company is collaborating with Colombia’s state-owned pharmaceutical company VECOL to transfer technology for its proprietary varicella vaccine "Sky Varicella" and establish local production infrastructure. SK bioscience is also working to expand its vaccine supply network through supply agreements with international organizations and others.


Internally, the company improved its work environment and enhanced employee welfare in conjunction with its headquarters relocation to Songdo this year. The report also includes the results of human rights impact assessments and the status of improvement initiatives implemented since 2023.


In the governance sector, the company strengthened its board-centered risk management system. SK bioscience established a framework for integrated management of both financial and non-financial risks, with regular reporting to the board of directors. It also expanded the management scope globally by incorporating ESG data from IDT Biologika, a German bio CDMO company.


As a result of these efforts, SK bioscience received an "A" grade for three consecutive years from the global ESG rating agency MSCI, and maintained an integrated "A" grade for four consecutive years from Korea Institute of Corporate Governance and Sustainability (KCGS).



Choi Jaeyoung, Head of Management Support at SK bioscience, stated, "We have included in this report the company’s achievements in pursuing sustainable growth and improving human health," adding, "By expanding global vaccine accessibility and strengthening ESG capabilities, we will continue to enhance both corporate value and social value."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing